Rudd Christopher E
Division of Immunology-Oncology, Centre de Recherche Hôpital Maisonneuve-Rosemont (CR-HMR), Montreal, QC, Canada.
Department of Microbiology, Infection and Immunology, Faculty of Medicine, Universite de Montreal, Montreal, QC, Canada.
Front Cell Dev Biol. 2021 Mar 15;9:626095. doi: 10.3389/fcell.2021.626095. eCollection 2021.
The past 25 years have seen enormous progress in uncovering the receptors and signaling mechanisms on T-cells that activate their various effecter functions. Until the late 1980s, most studies on T-cells had focused on the influx of calcium and the levels of cAMP/GMP in T-cells. My laboratory then uncovered the interaction of CD4 and CD8 co-receptors with the protein-tyrosine kinase p56 which are now widely accepted as the initiators of the tyrosine phosphorylation cascade leading to T-cell activation. The finding explained how immune recognition receptors expressed by many immune cells, which lack intrinsic catalytic activity, can transduce activation signals via non-covalent association with non-receptor tyrosine kinases. The discovery also established the concept that a protein tyrosine phosphorylation cascade operated in T-cells. In this vein, we and others then showed that the CD4- and CD8-p56 complexes phosphorylate the TCR complexes which led to the identification of other protein-tyrosine kinases such as ZAP-70 and an array of substrates that are now central to studies in T-cell immunity. Other receptors such as B-cell receptor, Fc receptors and others were also subsequently found to use kinases to control cell growth. In T-cells, p56 driven phosphorylation targets include co-receptors such as CD28 and CTLA-4 and immune cell-specific adaptor proteins such as LAT and SLP-76 which act to integrate signals proximal to surface receptors. CD4/CD8-p56 regulated events in T-cells include intracellular calcium mobilization, integrin activation and the induction of transcription factors for gene expression. Lastly, the identification of the targets of p56 in the TCR and CD28 provided the framework for the development of chimeric antigen receptor (CAR) therapy in the treatment of cancer. In this review, I outline a history of the development of events that led to the development of the "TCR signaling paradigm" and its implications to immunology and immunotherapy.
在揭示激活T细胞各种效应功能的受体和信号传导机制方面,过去25年取得了巨大进展。直到20世纪80年代末,大多数关于T细胞的研究都集中在T细胞中钙的流入以及cAMP/GMP的水平上。随后,我的实验室发现了CD4和CD8共受体与蛋白酪氨酸激酶p56的相互作用,现在这一发现已被广泛接受为导致T细胞激活的酪氨酸磷酸化级联反应的起始因素。这一发现解释了许多缺乏内在催化活性的免疫细胞所表达的免疫识别受体如何通过与非受体酪氨酸激酶的非共价结合来转导激活信号。该发现还确立了蛋白酪氨酸磷酸化级联反应在T细胞中起作用的概念。在此基础上,我们和其他人随后表明,CD4-和CD8-p56复合物使TCR复合物磷酸化,这导致了其他蛋白酪氨酸激酶如ZAP-70以及一系列底物的鉴定,这些底物现在是T细胞免疫研究的核心。随后还发现其他受体,如B细胞受体、Fc受体等也利用激酶来控制细胞生长。在T细胞中,p56驱动的磷酸化靶点包括共受体如CD28和CTLA-4以及免疫细胞特异性衔接蛋白如LAT和SLP-76,它们起到整合表面受体近端信号的作用。CD4/CD8-p56在T细胞中调节的事件包括细胞内钙动员、整合素激活以及基因表达转录因子的诱导。最后,TCR和CD28中p56靶点的鉴定为嵌合抗原受体(CAR)疗法在癌症治疗中的发展提供了框架。在这篇综述中,我概述了导致“TCR信号范式”发展的事件历程及其对免疫学和免疫治疗的影响。